Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a new
strategic collaboration and worldwide license agreement with
MediLink Therapeutics (Suzhou) Co., Ltd. (“MediLink”) to use
MediLink’s TMALIN® antibody-drug conjugate (ADC) platform for the
development of a novel LRRC15 ADC, ZL-6201, consisting of an
antibody discovered by Zai Lab.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20250109316500/en/
Through this collaboration, Zai Lab further expands its global
oncology pipeline with another potential first-in-class ADC
targeting multiple solid tumors and addressing significant unmet
medical needs. ZL-6201 has demonstrated encouraging preclinical
data with an IND expected to be filed in 2025.
“MediLink has built a differentiated proprietary ADC technology
platform, and we are excited to broaden our global partnership,”
said Rafael G. Amado, M.D., President, Head of Global Research and
Development at Zai Lab. “Building on the promising findings from
our ongoing clinical trials for ZL-1310, this new collaboration
demonstrates our continued focus on developing cancer therapies
with ADC drugs and enriches our global oncology pipeline to address
unmet medical needs. We look forward to working with MediLink to
advance this compound into the clinic soon.”
“Zai Lab’s strong commitment to innovation and proven track
record of global development impressed us through our existing
collaboration,” said Tony Xue, PhD, CEO at MediLink. “This new
partnership further validates our technology and enhances our
strategic partnership. We believe our collaboration with Zai Lab
will bring this innovative therapy to patients worldwide.”
About LRRC15
Leucine-rich repeat-containing protein 15 (LRRC15) is a type I
transmembrane protein involved in cell-cell and cell-extracellular
matrix (ECM) interactions. It is overexpressed in various
mesenchymal tumors such as sarcoma, glioblastoma and melanoma,
where it promotes tumor metastasis. Additionally, LRRC15 is
upregulated in cancer-associated fibroblasts (CAFs) across various
cancer types, contributing to immune-excluded and
immune-suppressive tumor microenvironment (TME). This makes LRRC15
an appealing target for cancer therapy.
About Zai Lab in ADC
Zai Lab is building a portfolio of potential first- and/or
best-in-class ADCs around the world. In addition to this
next-generation ADC, the company has one near to commercial stage
asset TIVDAK (tisotumab vedotin) and two next-generation ADC
programs, ZL-1310 and ZL-6301, with exclusive worldwide rights.
ZL-1310, a potential first-in-class ADC, is an investigational
DLL3-targeted ADC being developed in a Phase 1 trial. Zai Lab
presented encouraging efficacy and safety results for ZL-1310 from
the ongoing Phase 1 study in patients with recurrent
extensive-stage small cell lung cancer (SCLC) at the 2024
EORTC-NCI-AACR (ENA) Annual Symposium.
About Zai Lab
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative,
research-based, commercial-stage biopharmaceutical company based in
China and the United States. We are focused on discovering,
developing, and commercializing innovative products that address
medical conditions with significant unmet needs in the areas of
oncology, autoimmune disorders, infectious diseases, and
neuroscience. Our goal is to leverage our competencies and
resources to positively impact human health in China and
worldwide.
For additional information about Zai Lab, including our
products, business activities and partnerships, research, and other
events or developments, please visit www.zailaboratory.com or
follow us at www.twitter.com/ZaiLab_Global.
Zai Lab Forward-Looking Statements
This press release contains forward-looking statements relating
to our future expectations, plans, and prospects, for Zai Lab,
including, without limitation, statements relating to our prospects
and plans for developing and commercializing next generation ADCs,
the potential benefit of ADCs, and the potential treatment of solid
tumors. All statements, other than statements of historical fact,
included in this press release are forward-looking statements, and
can be identified by words such as “aim,” “anticipate,” “believe,”
“could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,”
“plan,” “possible,” “potential,” “will,” “would,” and other similar
expressions. Such statements constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements are not guarantees or
assurances of future performance. Forward-looking statements are
based on our expectations and assumptions as of the date of this
press release and are subject to inherent uncertainties, risks and
changes in circumstances that may differ materially from those
contemplated by the forward-looking statements. We may not actually
achieve the plans, carry out the intentions or meet the
expectations or projections disclosed in our forward-looking
statements, and you should not place undue reliance on these
forward-looking statements. Actual results may differ materially
from those indicated by forward-looking statements as a result of
various important factors, including but not limited to (1) our
ability to successfully commercialize and generate revenue from our
approved products, (2) our ability to obtain funding for our
operations and business initiatives, (3) the results of our
clinical and pre-clinical development of our product candidates,
(4) the content and timing of decisions made by the relevant
regulatory authorities regarding regulatory approvals of our
product candidates, (5) risks related to doing business in China,
and (6) other factors identified in our most recent annual and
quarterly reports and in other reports we have filed with the U.S.
Securities and Exchange Commission (SEC). We anticipate that
subsequent events and developments will cause our expectations and
assumptions to change, and we undertake no obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events, or otherwise, except as may be required
by law. These forward-looking statements should not be relied upon
as representing our views as of any date subsequent to the date of
this press release.
Our SEC filings can be found on our website at
www.zailaboratory.com and on the SEC’s website at www.SEC.gov.
Trademarks
All trademarks and registered trademarks referenced within are
property of their respective owners.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250109316500/en/
For more information, please contact:
Investor Relations: Christine Chiou / Lina Zhang +1 (917)
886-6929 / +86 136 8257 6943 christine.chiou1@zailaboratory.com /
lina.zhang@zailaboratory.com
Media: Shaun Maccoun / Xiaoyu Chen +1 857 270 8854 / +86
185 0015 5011 shaun.maccoun@zailaboratory.com /
xiaoyu.chen@zailaboratory.com
Zai Lab (NASDAQ:ZLAB)
過去 株価チャート
から 12 2024 まで 1 2025
Zai Lab (NASDAQ:ZLAB)
過去 株価チャート
から 1 2024 まで 1 2025
